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    Induced pluripotent stem cell (iPSC) technology is revolutionizing medical 
science, allowing the exploration of disease mechanisms and novel  
therapeutic molecular targets, and offering opportunities of drug discovery 
and proof-of-concept studies in drug development. This review focuses on 
the recent advancements in iPSC technology including disease modeling and 
control setting in its analytical paradigm. We describe how iPSC technology 
is integrated into existing paradigms of drug development and discuss the 
















    The ability of cells to differentiate into various cell types―known as 
"pluripotency"―is a hallmark of embryonic stem cells (ESCs). Stem cells 
belong to one of two major categories according to their potency of 
differentiation: organ-specific stem cells and pluripotent stem cells. Organ-
specific stem cells generally have limited potential for growth and 
differentiation. In contrast, pluripotent stem cells, such as ESCs1-3 and 
induced pluripotent stem cells (iPSCs),4-6 replicate in culture dishes and are 
theoretically capable of giving rise to any of the cell types found in the body 
(Figue 1).   
    The development of cellular reprogramming techniques leading to iPSCs 
has dramatically changed the landscape of stem cell research and 
application by providing a modality that circumvents the two major issues 
hampering fulfillment of the great potential of human ESCs.4-6 One is the 
ethical issue associated with the derivation of human ESCs from human 
fertilized eggs, and the other is the immunological incompatibility between 
ESC-derived donor organs or cells and the recipients because of  
histocompatibility-antigenic factors.4-6 As iPSCs are transforming the field 
of regenerative medicine, the reprogramming approach is also becoming a 
platform for drug discovery research.    
 
II. Discovery of iPSCs 
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II-1. Reprogramming inducers 
     Transduction of four genes encoding transcription factors highly 
functional in ESCs (i.e., Oct3/4, Sox2, Klf4, and c-Myc) was discovered to be 
sufficient to trigger reprogramming of both mouse and human somatic cells 
and to generate cells closely resembling the respective ESCs.4-6 The term 
coined for these reprogrammed ESC-like cells was “iPSCs”4. Subsequent 
research from our laboratory as well as from others has revealed several 
alternative methods for generating iPSCs.7-9  
Among the quartet of transcription factors involved in reprogramming9, 
Oct3/4 is expressed specifically in ESCs and germ cells but not in somatic 
cells.9 The forced expression of Oct3/4 in mouse or human Sox2-expressing 
neural stem cells can give rise to iPSCs, albeit with low reprogramming 
efficiency.9 There are reports of iPSC generation even in the absence of the  
Oct3/4 transgene, but the efficiency of generation is very low.  
Sox2 , which is a key partner of Oct3/4, is expressed almost exclusively in  
ESCs, germ cells, and nerve cells. The deletion of Sox2 causes the death of 
the embryo, suggesting its crucial role in embryogenesis.9 Sox family 
proteins, including Sox2, show functional overlap with each other. Although 
the conventional reprogramming method requires Sox2 transgene, 
inhibition of the transforming growth factor beta (TGF-) was shown to be 
capable of replacing Sox2 in reprogramming mouse embryonic fibroblasts.9 
Moreover, in some cell types, such as neural stem cells, melanocytes, and 
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melanoma cells, Sox 2 transgene is not necessarily a requirement for iPSC 
generation.9 These findings indicate the opportunistic nature of Sox 
transgene requirement in iPSC reprogramming. 
Kruppel-like transcription factor 4 (Klf4) is a downstream target gene of 
the signaling pathway of the cytokine leukemia inhibitory factor―Stat3. 
Klf4 has overlapping functions with other Klf transcriptional factors (Klf2 
and Klf5).10  During the reprogramming process, Klf4 binds to the Oct3/4-
Sox2 complex11, and together with homeobox protein PBX1, it underpins 
iPSC identity by regulating expression of Nanog, one of the pluripotency-
defining proteins12. The Klf4 transgene is not necessary for reprogramming 
under certain conditions such as histone deacetylase inhibition13,14 and the 
absence of the tumour suppressor gene, Trp53.15  
The reprogramming process is highly enhanced by c-Myc,16 although its 
inclusion in the reprogramming process should be discouraged, given its 
clear oncogenic potential. c-Myc expression is ubiquitous, in contrast to the 
other Myc family members, N- and L-Myc.9 L-Myc, and c-Myc mutants, all 
of which have little transformation activity, were shown to promote the 
generation of human iPSCs with more efficiently and specifically as 
compared with wild-type c-Myc.7  
For these reasons, the original quartet of reprogramming factors (Oct3/4, 
Sox2, Klf4 and c-Myc) are not necessary under certain conditions, and could 
be modified accordance with the experimental context. Clearly, it is 
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necessary to obtain a better understanding of the mechanisms underlying 
somatic cell reprogramming in order to fully validate the iPSC technology.  
 
II-2. iPSC/ESC differentiation repertoire and tumorigenicity 
    In vitro culture and the differentiation of stem cells provide us with 
opportunities for disease modeling, drug discovery, and cell replacement 
therapy. The generation of specific functional cell types from ESCs/iPSCs 
has been demonstrated, including neural cells, vascular endothelia, smooth 
muscle cells, cardiomyocytes, hematopoietic cells, pancreatic insulin-
producing cells, and hepatocyte-like cells.17-23 The current differentiation 
repertoire includes more than 200 types of somatic cells.24 These cells may 
be applied in regenerative medicine, and work is ongoing to overcome the 
remaining hurdles. Significant challenges in iPSC-based regenerative 
medicine include (i) the tumorigenic potential inherent to the 
reprogramming methods, (ii) the difficulty in achieving highly targeted 
differentiation, and (iii) the complexity of cellular transplantation 
techniques.25  
     Eradicating the tumorigenic potential of iPSC-derived cells is of 
fundamental importance to further enhance clinical transfer of the 
technology.   Interestingly, the teratoma-forming propensities of secondary 
neurospheres, after transplantation into the brains of nonobese/severe 
combined immunodeficient  mice, vary significantly depending on the origin 
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of the tissue from which the iPSCs were derived.26 For example, secondary 
neurospheres from iPSCs generated from adult tail-tip fibroblasts of mice  
showed the highest propensity for tumorigenicity, whereas those from iPSCs 
originating from mouse embryonic fibroblasts and gastric epithelial cells 
showed the lowest such propensity, the latter being comparable, in this 
regard, to those obtained from ESCs.  Secondary neurospheres from 
hepatocyte iPS cells showed an intermediate teratoma-forming propensity.  
The use of iPSCs in regenerative medicine clearly requires further 
improvement of differentiation protocols in order to minimize  
tumorigenicity.  
     
III. iPSC-based disease modeling  
  There are many potential causes for the failed translation of drug 
discovery from levels of molecular and animal models to human 
therapeutics. In particular, the success of preclinical phases of drug 
development is based on animal models.27 Furthermore, <10% of the 
compounds that enter the clinical phase of testing reach the stage of market  
approval; the estimated cost of the entire drug development process is 
US$1.2-1.7 billion per drug.27-29 Drug discovery/development platforms 
using iPSC-based disease models could be useful in filling the gap between 
animal models and clinical trials.     
 iPSC technology is expected to provide innovative tools for drug 
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development via high-throughput therapeutic/toxicity screening, using 
differentiated cells from patient-derived iPSCs. This disease-modeling 
approach to drug discovery will also increase our understanding of disease 
progression and biology in specific cell types, which could possibly lead to 
redefining known aspects of diseases.30 Patient-specific iPSCs provide not 
only genetic information but also potential phenotype attributes. In addition, 
iPSCs can be generated from patients irrespective of whether the disease is 
in the familial or the sporadic form. Drug screening platforms can be 
developed to test compounds (including biologics such as small hairpin 
RNAs) that are able to make the disease-related phenotype revert to that of  
the non-disease control.30 
     The available lines of human ESCs are variable with regard to epigenetic 
information, expression profile, and differentiation propensity.31,32 
Significant intrinsic variability also remains in iPSC lines, and abnormal 
expression of imprinted genes has been detected in a significant number of 
them.33 These inter-iPSC differences were attributed to the introduction of 
reprogramming factors using randomly integrating viral vectors, and/or to 
persistent donor cell gene expression.34 However, even if iPSCs are 
generated in the absence of integrating factors, intrinsic variability  
remains,35-37 including in the matter of neuronal differentiation 
competence.38 Moreover, expression profile analysis of integration-free 
human iPSCs has shown an expression signature in iPSCs that is distinct 
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from those of both the original population and standard human ESCs.35 It is 
also reported that there is a strong correlation between gene expression 
signatures and specific laboratories, in both ESC and iPSC lines, because of  
differences in the in vitro microenvironment.39 These observations suggest 
that further dissecting the intrinsic variability of iPSCs may provide clues 
regarding the wild-type iPSCs that would be the most suitable as 
experimental controls and the number of control lines that should be 
obtained for each experiment.35 Despite these variations, however, many 
lines of disease-specific iPSCs are being generated,40 given that several 
studies have actually recapitulated the phenotypes of diseases in the iPSC-
derived targeted cell population and that this approach now finds a place on 
the drug development platform as a useful tool to complement in vivo 
experiments. (Table 1). 41-46 
    To avoid both inter- and intrapatient clonal variations of iPSCs, it is 
necessary to purify targeted cells by fluorescence-activated cell sorting or 
magnetic sorting using fluorescent or magnet-labeled antibodies27 or by 
high-content analysis.47,48 The control of the prominent heterogeneity of iPS-
derived differentiated cells presents a technological challenge; this 
continues to be the major limitation of standardized high-throughput 
screening, although further modifications in differentiation protocols are 
under way in our laboratory. 
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IV. iPSC-based toxicity screening      
    The progressive attrition of medicinal products in the long pipeline 
between ‘hit’ identification and the market has become one of the concerns 
of the pharmaceutical industry in the past decade.48 The development cost 
of a marketable product is continuing to grow.27-29,49 In 2001, development 
was abandoned because of lack of efficacy in 30% of the medicines that 
entered clinical trials and in another 30% because of safety concerns49 such 
as cardiotoxicity and hepatotoxicity. The effective development of new drugs 
therefore requires predictive toxicity assays of adequate accuracy during 
preclinical testing. The use of human iPSCs and robust protocols to 
differentiate them into cardiomyocytes and hepatocytes should be able to 
provide straightforward assays for analyzing certain aspects of drug 
metabolism and for assessing probable side effects. However, technological 
hurdles still exist with respect to achieving the desired maturity of 
differentiated cells50 and minimizing the substantial heterogeneity of iPS-
derived differentiated cells for the assay. Despite these limitations, 
significant progress has been made.  
    The drug-induced blockade of the ether-a-go-go related gene 1 (hERG1) 
channel is reportedly associated with an increased duration of ventricular 
repolarization, causing prolongation of the QT interval (i.e., long QT 
syndrome).51-54 Data related to the electrophysiological capacity and 
responsiveness of human iPSC-derived cardiomyocytes in response to 
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several cardiac and noncardiac drugs have been reported.51-54 Cardiac 
toxicity screening tools based on these approaches will soon become 
available.  
       The efficient generation of functional hepatocyte-like cells from iPSCs 
has been also reported.20,21  The use of three-dimensional culture as well as 
co-culture systems (e.g., associating Kupffer and/or endothelial cells with 
hepatocytes in order to mimic the in vivo hepatic context) are among the 
strategies now recognized to enhance the generation of even more mature 
cells.49  
     To establish toxicity screening tools using iPSC technology, validation is 
essential.  In particular, it is crucial to show high fidelity of the iPSC-based 
toxicity screening tools in reproducing, in vitro, the toxicity profiles of “hit”  
drugs that had been eliminated from the development pipeline because of  
safety concerns.   
 
V. Challenges in iPSC-based approaches 
V-1. Aging process and environmental effects  
     Several diseases that are characterized by onset in early life have been  
successfully modeled using iPSC technology.41-46 On the other hand, in some 
diseases (including neurodegenerative diseases) that are age dependent, 
patient-specific iPSC-derived neural cells may not immediately manifest the 
disease phenotype as compared with normal control cells, under basal cell 
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culture conditions.30,55,56 This may also apply to drug toxicity that shows 
age-dependent susceptibility. Identification of disease/toxicity-related 
phenotypes in short-term settings in vitro appears particularly challenging, 
but it may be possible to achieve by mimicking the aging process with 
stressors such as oxygen reactive species, proinflammatory factors, or 
toxins.30,55,56 Identification of new and more effective and relevant stressors 
that can accelerate the process of eliciting phenotypes in models of late-
onset diseases will therefore be an important goal for future disease 
modeling.30, 55,56 
  Even patients with monogenetic diseases manifest large genotype–
phenotype variability. Therefore, it would be more difficult to establish 
disease modeling from sporadic-disease iPSCs, given the complexity of the 
different genetic backgrounds and environmental cues involved.27,30  It will 
be both challenging and exciting to examine whether the same phenotype as 
seen in monogenic-disease modeling could be recapitulated in sporadic-
disease-iPSC-derived modeling by reproducing environmental effects in 
vitro.27,30,55,56 
 
V-2. Definition of “control” 
    Whether in selecting a therapeutic or in toxicity assays using patient-
specific iPSC-derived cells, the use of well-defined, non-disease control cells 
is crucial. Recent genome-wide association studies57 have demonstrated that 
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every person has disease-relevant single-nucleotide polymorphisms, and it 
is therefore impossible to categorically define iPSCs that represent perfect 
non-disease control.  
    Nonetheless, we think that the following two approaches are valid for 
deriving iPSC-positive (disease) and negative (non-disease) controls: (i) 
deductive and (ii) inductive. Deductive controls would include non-disease 
iPSC/ESC lines with modification (e.g., disease gene transgenic and disease 
gene knock-in), disease gene-corrected iPSC /ESC lines generated from 
disease iPSC/ESCs, and iPSCs with non-disease alleles from an individual 
patient in somatic mosaicism (Table 2). Deductive approaches define 
negative and positive controls in similar genetic backgrounds, providing 
benchmarks of disease modeling to specify differences between disease and 
non-disease control, whereas contributors other than the targeted gene(s) 
are not considered. On the other hand, inductive controls may be non-
disease iPS cell lines or iPSCs from healthy individuals or from other 
patients (positive control). This approach could be less complicated than the 
deductive method, especially if noise from iPSC variations can be further 
reduced.  
    For the deductive control setting of disease modeling, the tools for 
achieving expression or knockout of disease genes in hiPSCs/ESCs by 
random integration of vectors (including viruses, bacterial artificial 
chromosomes, synthetic gene delivery reagents, and a 
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transposon/transposase system) are useful.58-60 Also, the current 
development of engineered nucleases makes targeted genome modification 
an attractive tool with therapeutic potential that may go beyond the 
development of drug screening tools.58  
 
VI. iPSC-based novel drug development platform 
VI-1. iPSC-based in vitro Phase III 
    Diseases can be divided into rare, monocausal genetic diseases and a 
large group of sporadic, multifactorial diseases. No large-scale disease 
modeling is currently available for the latter group. Technological advances 
in rapid and easy iPSC generation on a large scale will realize the 
possibility of both in vitro  phase III and case-control studies by using non-
disease and disease controls derived from age/gender-matched donors or 
from family members regardless of age/gender.30 One of the factors 
facilitating the process could be to obtain a blood sample from each patient 
in order to generate iPSCs. iPSC generation from peripheral blood drops 
from each patient would allow case-control studies to be carried out, 
although several issues must still be resolved prior to the use of iPSCs from 
peripheral blood cells.61-64 First, the differentiation potency of these iPSCs 
must be analyzed further.61 Peripheral blood-derived iPSCs may preserve 
epigenetic memories of having been blood cells and may therefore exhibit 
preferred differentiation into hematopoietic lineages rather than into other 
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cell types.61,65 Another issue is how long and to what extent iPSC clones 
from terminally differentiated cells can be expanded.61-64 Finally, the effect 
of the presence of pre-existing T-cell receptor rearrangements on the 
properties of iPSC or differentiated cells needs to be determined.61,66 Besides 
minimizing the invasive biopsy procedures, reducing the time requirement 
for iPSC differentiation, resulting in lower costs, would be essential for large 
cohort studies,  potentially leading to the discovery of novel drug targets.  
 
VI-2. iPSC and animal model  
    Cell lines and animal models contribute to the exploration of disease 
mechanisms and drug development for various diseases. However, the 
animal models do not always demonstrate the same phenotypes as those 
seen in humans.55 For instance, in mice the type and/or distribution of 
cardiac ion channels are different from those in humans, demonstrating a 
relatively shorter duration of action potential and higher heart rate (600 
bpm).67 An in vitro analysis of human cardiomyocytes is therefore critical to  
an understanding of the mechanism of genetic-related arrhythmias in 
humans.67 Also, compounds that demonstrate significant benefit in animal 
models may fail to show effectiveness in clinical trials in humans.55,68,69 The 
use of transgenic mice of mutant superoxide dismutase (SOD1), a gene 
found to be associated with amyotrophic lateral sclerosis,70 enabled the 
identification of several compounds that relieve the disease phenotype, 
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including vitamin E and creatine.71-73 However, when these compounds were 
tested in humans, no clinical improvements were observed.71-73 The toxicity 
of compounds is sometimes missed in cell lines and animal models because  
specific interactions with human biological processes cannot be 
recapitulated in these systems.27 Also, the use of animal models for toxicity 
assays may be ethically problematic, the animals may be expensive to 
purchase and maintain, and the process may be difficult to automate.27 
Clearly, we require different drug screening models that complement these 
systems and represent the human condition with high fidelity.74 iPSCs are 
expected to fulfill these requirement and are amenable to the demands of 
drug development. There are nonetheless great advantages associated with  
cell line-based models (which could be used for homologous culture, yielding 
reproducible results) and for animal models (which provide information 
regarding optimal time window, drug delivery, metabolism, etc.) (Figure 2). 
Integrated drug screening systems, consisting of disease-specific iPSC-based 
models as well as cell lines and animal models, would greatly enhance the 
efficiency of translational drug research.  
 
VI-3. Personalized medicine 
    The striking advantage of using iPSCs rather than ESC-based 
approaches is that iPSCs can be derived from any individual with relative 
ease, thereby allowing development of a personalized study platform on 
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individual genomic information. iPSCs and differentiated cells from the 
iPSCs retain their personal identity, like an alter ego, suggesting that iPSC 
technology can be applied to disease-, patient-, and finally person-specific 
approaches to examine the individual differences in 
pharmacokinetic/pharmacodynamic features (Figure 3). Given that everyone 
will almost certainly become a patient at least once in his or her lifetime,  
individual iPSC-based predictive therapeutic and toxicity profiling of all 
drugs available in multiple cell types will be a logical and attractive 
approach. This “pharmaco-iPSCellomic” analysis (Figure 4) could eventually 
be available in an array-based format for high-throughput assay before 
specific drug therapy is prescribed for a certain disease condition.   
     
VII. Conclusion 
    The potential of the iPS cell technology in drug discovery is enormous.75 
At the same time, the technology is still in its infancy with numerous 
challenges to overcome before its clinical translation is complete. The long 
journey has just begun. It may take years to reach the eventual goals, but 
the iPSC technology itself, combined with existing methods and models, will 
begin to contribute to the development of new cures. 
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Figure 1  
Generation of induced pluripotent stem cells (iPSCs) and their differentiation potential. 
iPSCs are derived from easily accessible somatic cells. In contrast to organ-specific stem 
cells, pluripotent stem cells such as embryonic stem cells and iPSCs show the ability to 
differentiate into many different cell types in culture. This allows in vitro generation of 
specific tissue cell types with the characteristics of the disease phenotype, from 
patient-derived iPSCs. 
 
Figure 2  
Combined approach involving animal models and induced pluripotent stem cell (iPSC) 
technology. The new iPSC technology is complemented by a drug development strategy 
in preclinical settings that uses animal models and other conventional approaches. 
 
Figure 3  
Personalized medicine based on induced pluripotent stem cell (iPSC) technology. iPSC 
technology is highly amenable to individualized approaches. Person-specific iPSCs can 
be derived, differentiated into specific cell types, and used for therapeutic/toxicity 
response assays. 
 
Figure 4  
”Phamaco-iPSCellomics” by person-specific iPSCs. iPSCs derived from individual 
subjects/patients can be differentiated into multiple cell types, thereby providing a 
personalized iPS-cellome platform. This cell-based system can be used for drug 





Table 1 Disease modeling using disease-specific iPSCs.
AD: autosomal dominant, AR: autosomal recessive, IA: immunological analysis, IGF-1: insulin-like growth factor 1, iPSC: induced pluripotent stem cell, 






1) Reduced no. of glutamatergic synapse and morphological alterations (synapsin puncta at
dendrites), rescued by IGF-1 (ng/ml).
2) Reduced RTT protein level/cell size, and rescue by gentamicin (100 mg/ml) at Q244X clone.
3) Reduced activity-dependent calcium transients.




























Recapitulated phenotype / proof of drug efficacy
AR
AR Infancy
1) Increased abnormal splicing in differentiated neural crest.
2) Decreased no. (%) of ASCL1+, Tuj1+ neurons.
3) Migratory dysfunction (scratch assay).
4) Partial Rescue phenotype 1, 2 with 100 mmol/l kinetin.
 1) Unsuccessful at obtain iPSCs from patient’s fibroblast
→after ‘in vitro  genetic correction’ of patient’s fibroblast,
Successful in obtaining iPSCs (chromosomal instability).
 2) Differentiate into CD34+/hematopoietic progenitors.





2) Decreased SMN protein level (evaluated with WB/IA).






1) Enlarged cell size of differentiated cardiomyocyte.
2) Inactivated RAS-MAPK pathway (bFGF induction).
1) Elongated telomere in iPSCs (TERT/TERC↑).
2) Shortened telomere after differentiation (TERT/TERC↓).
Table 2 proposed definition of “control” in induced pluripotent stem cell research  
 
Deductive approach  
  Embryonic stem cell line with and without disease-introducing genetic modification  
  Non-disease induced pluripotent stem (iPS) cell line with and without disease-introducing genetic 
modification  
  Disease iPS cell with and without disease-correcting genetic modification  
  iPS cell from somatic mosaic with and without disease allele  
 
Inductive approach  
  iPS cell from a patient and a disease-free family member  
Disease genetic risk-ascertained iPS cell lines (preferably as a risk-absent non-disease control)  
iPS cell lines from disease-phenotyped individuals (healthy or disease control)  
 
